Equity Overview
Price & Market Data
Price: $15.66
Daily Change: -$0.28 / 1.79%
Range: $15.35 - $16.08
Market Cap: $2,676,654,336
Volume: 1,081,479
Performance Metrics
1 Week: -6.62%
1 Month: 13.64%
3 Months: -19.77%
6 Months: -45.89%
1 Year: -37.61%
YTD: -36.78%
Company Details
Employees: 362
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for graves' disease and thyroid eye disease. The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relating to IMVT-1402 and batoclimab. Immunovant, Inc. was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.